文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

自体CD7嵌合抗原受体T细胞治疗后达完全缓解的难治复发性T细胞急性淋巴细胞白血病/淋巴母细胞淋巴瘤患者接受异基因造血干细胞移植的安全性和疗效研究

A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T-cell therapy.
PubMed 文献 · Br J Haematol · 2024-04-13

本研究纳入34例经自体CD7 CAR-T治疗达完全缓解后接受异基因造血干细胞移植的难治复发性T细胞急性淋巴细胞白血病/淋巴母细胞淋巴瘤患者,与124例化疗达完全缓解后移植的连续患者对比。两组2年总生存率、无白血病生存率、非复发死亡率和复发率均无显著差异。CD7 CAR-T组年龄≤14岁患者2年总生存率和无白血病生存率均达87.5%。

要点

  • CD7 CAR-T后桥接异基因造血干细胞移植的2年总生存率为61.9%,与化疗后移植的67.6%无显著差异。
  • 两组2年无白血病生存率、非复发死亡率和复发率均无显著差异,CD7 CAR-T未增加非复发死亡。
  • CD7 CAR-T组年龄≤14岁患者2年总生存率和无白血病生存率均达87.5%。

核心结论

  • CD7 CAR-T治疗后桥接异基因造血干细胞移植对难治复发性T-ALL/LBL患者有效且安全,结局与化疗达完全缓解后移植者相当,且不增加非复发死亡。

研究设计与样本

  • 研究纳入34例经自体CD7 CAR-T治疗达完全缓解后接受异基因造血干细胞移植的难治复发性T-ALL/LBL患者,并与124例化疗达完全缓解后接受异基因造血干细胞移植的连续T-ALL/LBL患者进行对比。

主要发现

  • CD7 CAR-T组与化疗组2年总生存率分别为61.9%(95% CI,44.1-78.1)和67.6%(95% CI,57.5-76.9),p=0.210。
  • CD7 CAR-T组与化疗组2年无白血病生存率分别为62.3%(95% CI,44.6-78.4)和62.0%(95% CI,51.8-71.7),p=0.548。
  • CD7 CAR-T组与化疗组非复发死亡率分别为32.0%(95% CI,19.0-54.0)和25.3%(95% CI,17.9-35.8),p=0.288。
  • CD7 CAR-T组与化疗组复发率分别为8.8%(95% CI,3.0-26.0)和15.8%(95% CI,9.8-25.2),p=0.557。
  • CD7 CAR-T组年龄≤14岁患者2年总生存率和无白血病生存率均达87.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD7-targeted chimeric antigen receptor T-cell (CAR-T) therapy has shown promising initial complete remission (CR) rates in patients with refractory or relapsed (r/r) T-cell acute lymphoblastic leukaemia and lymphoblastic lymphoma (T-ALL/LBL). To enhance the remission duration, consolidation with allogeneic haematopoietic stem cell transplantation (allo-HSCT) is considered. Our study delved into the outcomes of 34 patients with r/r T-ALL/LBL who underwent allo-HSCT after achieving CR with autologous CD7 CAR-T therapy. These were compared with 124 consecutive T-ALL/LBL patients who received allo-HSCT in CR following chemotherapy. The study revealed that both the CAR-T and chemotherapy cohorts exhibited comparable 2-year overall survival (OS) (61.9% [95% CI, 44.1-78.1] vs. 67.6% [95% CI, 57.5-76.9], p = 0.210), leukaemia-free survival (LFS) (62.3% [95% CI, 44.6-78.4] vs. 62.0% [95% CI, 51.8-71.7], p = 0.548), non-relapse mortality (NRM) rates (32.0% [95% CI, 19.0-54.0] vs. 25.3% [95% CI, 17.9-35.8], p = 0.288) and relapse incidence rates (8.8% [95% CI, 3.0-26.0] vs. 15.8% [95% CI, 9.8-25.2], p = 0.557). Patients aged ≤14 in the CD7 CAR-T group achieved high 2-year OS and LFS rates of 87.5%. Our study indicates that CD7 CAR-T therapy followed by allo-HSCT is not only effective and safe for r/r T-ALL/LBL patients but also on par with the outcomes of those achieving CR through chemotherapy, without increasing NRM.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Cao XY, Zhang JP, Lu Y, et al. A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T-cell therapy. Br J Haematol. 2024. PMID: 38613241. doi:10.1111/bjh.19445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。